Slingshot members are tracking this event:
Amgen's (AMGN) BLINCYTO earns FDA approval for relasped or refractory B-cell acute lymphoblastic leukemia
Slingshot Insights Explained
Jul 13, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Blincyto, Fda Approval, Relapsed/refractory Acute Lymphoblastic Leuke